|
Researchers now know that cancer cells have several unique characteristics:
they require new blood vessels to deliver oxygen and nutrients; they grow
uncontrollably; they travel throughout the body; and they escape programmed
cell death, a natural process by which the body rids itself of damaged or
unwanted cells. Robust preclinical data has shown that several compounds in
Abbott’s oncology pipeline may interfere with these processes.
Positive data on two such Abbott compounds, ABT-263 and ABT-888, was
presented by both independent and Abbott scientists at the American Association
for Cancer Research (AACR) Annual Meeting, held April 14-18 in Los Angeles,
California.
Discovered by Abbott scientists and currently in clinical development,
ABT-263 may correct defects in cancer cells that allow them to escape
programmed death.
Also developed by Abbott researchers, ABT-888 may help prevent DNA repair in
cancer cells, thereby increasing the effectiveness of common cancer therapies
such as radiation and alkylating agents.
|
 |
| Preclinical data has shown that
ABT-263 (Abbott’s Bcl-2 family protein inhibitors)
bind to Bcl-2 proteins, restoring cell death to cancerous
cells. |
|